India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report
Indian markets moved higher in a quarterly results development.
· Business Standard Mkts
India's pharma and healthcare sector recorded 87 deals worth $4.3 billion in Q3 2026, as private equity activity surged and public market fundraising gained momentum.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- A market-wide development: it reaches beyond any single stock.
- Sectors in the story: Pharma & Healthcare.
Pharma & Healthcare
1M -3.2% · 3M -2.1%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Syngene International shares surge 12%, biggest 1-day gain in 6 years; what drove the rally despite a Q2 profit drop?
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
Meesho Q2 Results: Loss narrows to Rs 132 crore YoY, revenue rises 34%
Acutaas Chemicals among 5 stocks hitting 52-week highs; rallied up to 18% in a month
Pidilite Industries reports 7% YoY growth in net profit to Rs 626 crore